4. As of noon trading, Gilead ( GILD) is up $0.56 (1.00) to $56.81 on average volume Thus far, 8.2 million shares of Gilead exchanged hands as compared to its average daily volume of 11.5 million shares. The stock has ranged in price between $55.09-$57.10 after having opened the day at $56.34 as compared to the previous trading day's close of $56.25.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $83.1 billion and is part of the health care sector. The company has a P/E ratio of 30.4, above the S&P 500 P/E ratio of 17.7. Shares are up 48.3% year to date as of the close of trading on Tuesday. Currently there are 19 analysts that rate Gilead a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, increase in net income and growth in earnings per share. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Gilead Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you liked this article you might like

Bristol-Myers Squibb Stock Still a Beast?

There Are Good Opportunities in Stock Picking

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Achillion Shares Are Plunging on Termination of Hepatitis C Pact